The University of Texas MD Anderson Cancer Center announced its first-ever academic journal, Advances in Cancer Education & Quality Improvement. The journal will publish research, training program summaries, and quality improvement interventions for the oncology provider community.
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.
